ATAXIA UK — grant history
Latest income
£1.8m
Grants listed (FY2025)
2
Listed grants total
£78k
Accounts grants total
£78k
listed grants reconcile with the accounts totalextracted from its FY2025 accounts
Application guidance — from the funder’s own website
- How to apply: Ataxia UK does not accept unsolicited applications for research grants. The charity funds a wide variety of research projects, but the specific process for researchers to apply is not detailed on the provided pages, which only list currently funded projects.
What changed: FY2024 → FY2025
| Change | Grantee | FY2024 | FY2025 |
|---|---|---|---|
| new | Z-Institut du Cerveau et de laMoelle épinière-ICM | — | £68k |
| new | Z-Universidade de Lisboa | — | £10k |
| not listed | Dr Shiloh-Malawsky (University of North Carolina, US) | £35k | — |
| not listed | Dr Hubener-Schmid (University of Tubingen, Germany) | £30k | — |
| not listed | Prof Tremblay (Universite’ Laval, Canada) | £8k | — |
| not listed | Realise Advocacy consultancy | £6k | — |
| not listed | Dr Abeti and Prof Giunti (UCL, UK) | £5k | — |
| not listed | Dr Anjoumani-Virmouni (Brunel University) | £5k | — |
| not listed | Prof Clayton (Great Ormond Street Institute of Child Health, UK) | £5k | — |
| not listed | Dr Hauser (DZNE, Germany) | £4k | — |
Grants made, per its accounts filings
| Recipient | Year | Amount | Purpose |
|---|---|---|---|
| Z-Institut du Cerveau et de laMoelle épinière-ICM | FY2025 | £68k | Novel biomarkers of oxidative stress in ataxia; Identification of disease-associated single nucleotide polymorphisms in ataxin-3; Evaluating ribosome collisions on CAG expansions proteostasis and translational; Consultancy support with respect to preparing for Health Technology Assessment; Effect of targeting sphingolipid- metabolising enzymes in iPSC-derived sensory neurons model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) |
| Z-Universidade de Lisboa | FY2025 | £10k | Restoring NKX6-2 function by protein complementation: a proof-of-concept; Outcome measures in Mitochondrial disease and Spinocerebellar ataxias (R-PROMS) |
| Dr Shiloh-Malawsky (University of North Carolina, US) | FY2024 | £35k | Extension project “DRPLA Natural History and Biomarkers Study |
| Dr Hubener-Schmid (University of Tubingen, Germany) | FY2024 | £30k | Development and Validation of SIMOA-based total and mutant Ataxin-2 Immunoassay for biomarker studies in SCA2 and SCA3 |
| Prof Tremblay (Universite’ Laval, Canada) | FY2024 | £8k | Novel biomarkers of oxidative stress in Friedreich's ataxia |
| Realise Advocacy consultancy | FY2024 | £6k | Preparing for the health technology assessment process in FA |
| Dr Abeti and Prof Giunti (UCL, UK) | FY2024 | £5k | Exploring novel iron-mediated mechanisms to prevent cellular death in Friedreich’s ataxia |
| Dr Anjoumani-Virmouni (Brunel University) | FY2024 | £5k | Effect of targeting sphingolipid-metabolising enzymes in iPSC derived sensory neurones obtained from FRDA patients |
| Prof Clayton (Great Ormond Street Institute of Child Health, UK) | FY2024 | £5k | Novel biomarkers of oxidative stress in Friedreich’s ataxia |
| Dr Hauser (DZNE, Germany) | FY2024 | £4k | Identification of disease-associated single nucleotide polymorphisms in ataxin-3 |
| Dr Matassa University of Naples, Italy | FY2024 | £3k | Evaluating ribosome collisions on CAG expansions proteostasis and translational stress responses in Spinocerebellar Ataxia type 3 |
| Prof Marios Hadjivassiliou (Sheffield Teaching Hospitals NHS Trust, UK) | FY2023 | £38k | Improving the diagnosis and management of gluten ataxia |
| Dr Karen Anthony (University of Northampton, UK) | FY2023 | £31k | Evaluation of RNA trans-splicing as a therapeutic strategy for spinocerebellar ataxia type 1 |
| Dr Andreia Teixeira-Castro (University of Minho, Portugal) | FY2023 | £30k | Testing the multimodal anti-depressant vortioxetine as a therapeutic strategy to mitigate SCA3 |
| Dr Roderick Maas (Radboud University Medical Center, The Netherlands) | FY2023 | £30k | Looking beyond the central nervous system in SCA3: nerve and muscle ultrasound as potential imaging markers to quantify and monitor peripheral nervous system degeneration. |
| Prof Paola Giunti (University College London, UK) | FY2023 | £27k | Validating the therapeutic effect, a CAG repeat-targeting antisense oligonucleotide, on mitochondrial physiology in cellular models of DRPLA |
| Prof Paola Giunti (University College London, UK) | FY2023 | £25k | Determine mitochondrial metabolism in DRPLA: a possible novel therapeutic approach |
| UK Researchers | FY2023 | £7k | Nine bursaries of £750 each to UK researchers to help them attend the International Congress for Ataxia Research |
| Dr Francesca Salvatori (University of Ferrara, Italy) | FY2023 | £5k | Personalized gene editing approach for the treatment of Spinocerebellar Ataxia type 1 (SCA1) |
| Dr Pellerin (UCL) | FY2023 | £2k | Dr David Pellerin travel grant award of £1500 to attend and present an oral presentation at the American Academy of Neurology 2023 Annual Meeting. |
| Gordon Research Conference | FY2023 | £433 | $500 Sponsorship of CAG Triplet Repeat Disorders Gordon Research Conf and Seminar |
| University of North Carolina at Chapel Hill, USA | FY2022 | £131k | DRPLA Natural History and Biomarkers Study (DRPLA NHBS) |
| German Center for Neurodegenerative Diseases, Bonn, Germany | FY2022 | £80k | Assessment of ataxia severity under real-life conditions with SARAhome: A multicenter study in spinocerebellar ataxia type 3 (SCA3) |
| Institut du Cerveau et de la Moelle épinière (ICM), France | FY2022 | £61k | Preclinical development of an amelioration therapy for DentatorubroPallidoluysian Atrophy – Funding Extension |
| Instituto de Invesigacão e Inovacão em Saúde – i3S, Portugal | FY2022 | £30k | NanoSCA3: Development of brain-targeted nanobodies for application in spinocerebellar ataxia type 3 therapy |
| University of Brescia, Italy | FY2022 | £5k | Motor and cognitive outcomes of non-invasive transcranial alternate current stimulation by entrainment of cerebellar oscillation |
| University College London, UK | FY2022 | £5k | Brain pathology in an AIFM1 mutation causing Cowchock syndrome |
| Imperial College London, UK | FY2022 | £5k | Generation and characterization of a cardiomyocyte model for Friedreich’s ataxia to reveal the molecular mechanism of heart failure in patients |
| Newcastle University, UK | FY2022 | £5k | Balance and gait abnormalities in adult patients with mitochondrial disease and spinocerebellar ataxia type 6 |
| Centro de Biología Molecular Severo Ochoa, Madrid, Spain | FY2022 | £5k | Analysis of the mitochondrial dysfunction in FXN deficient neurones to generate a drug screening test |
| Strathclyde University, UK | FY2022 | £3k | A feasibility study of LSVT Artic to improve speech performance in people with progressive ataxia |